Additionally, the coexistence of mutations in genes that function within distinct DNA damage response pathways—such as homologous recombination repair (e.g., BRCA1/2) and mismatch repair (e.g., MSH2, MSH6)—may contribute to unique tumor biology and potential therapeutic vulnerabilities (El Tekle et al., 2021). This evidence concerns the gene BRCA1 and neoplasm.